A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor.
about
Targeting B-cell receptor signaling kinases in chronic lymphocytic leukemia: the promise of entospletinibThe role of idelalisib in the treatment of relapsed and refractory chronic lymphocytic leukemiaChronic Lymphocytic Leukemia: Exploiting Vulnerabilities with Targeted AgentsKnow the enemy as well as the weapons in hand: the aberrant death pathways and therapeutic agents in chronic lymphocytic leukemiaTargeted Therapies in Adult B-Cell MalignanciesTargeting chronic lymphocytic leukemia cells in the tumor microenviroment: A review of the in vitro and clinical trials to dateIdelalisib for the treatment of chronic lymphocytic leukemiaNovel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive reviewTherapeutic potential of new B cell-targeted agents in the treatment of elderly and unfit patients with chronic lymphocytic leukemiaGetting Syk: spleen tyrosine kinase as a therapeutic target.The p53 transcriptional pathway is preserved in ATMmutated and NOTCH1mutated chronic lymphocytic leukemias.Characterization of CLL exosomes reveals a distinct microRNA signature and enhanced secretion by activation of BCR signalingIbrutinib: a paradigm shift in management of CLL.Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease.Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL.Idelalisib for the treatment of non-Hodgkin lymphoma.PI3Kδ and PI3Kγ isoforms have distinct functions in regulating pro-tumoural signalling in the multiple myeloma microenvironment.Pharmacodynamic considerations of small molecule targeted therapy for treating B-cell malignancies in the elderly.Targeting non-receptor tyrosine kinases using small molecule inhibitors: an overview of recent advances.Targeting the mTOR Pathway in Leukemia.Inhibition of exportin-1 function results in rapid cell cycle-associated DNA damage in cancer cells.PRT062607 Achieves Complete Inhibition of the Spleen Tyrosine Kinase at Tolerated Exposures Following Oral Dosing in Healthy VolunteersSyk inhibitors in clinical development for hematological malignancies.The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia.Identification of spleen tyrosine kinase as a potential therapeutic target for esophageal squamous cell carcinoma using reverse phase protein arrays.
P2860
Q26744277-1696A1CC-31D5-4754-A3AF-183B3FF480FCQ26751006-F565998F-B2F2-4435-ABBD-03D8BC9AFBEAQ26764833-324E9501-B17B-4855-B0D5-928CD4DD1E9DQ26781895-18A2EC6C-8794-4BC0-BBE3-CD08249B822BQ26783195-9B2A3B14-D07F-45A2-AF50-98BAAAB7532EQ26798062-F296523B-6E32-4D99-B29D-FAD420689975Q27015826-D7AC6105-EA66-4419-9781-FD9E3FD58A56Q27304386-84DFB4B3-C48F-459F-A566-63A4005A0086Q28087378-D3584C20-095A-4367-B95F-D9AAAF3026ADQ33993750-DD18C03A-577E-475D-8E64-C8D573CFB225Q35149661-86412673-E583-431A-ABBF-780F00B6BEE8Q35634885-831CB7A0-BCDE-4C8F-8932-AC950987D860Q36739295-F226F9E1-4B1E-48F4-80FE-27EB0DF64D76Q36876967-3F6A5193-2384-4C43-B74C-38B6A2BE1C46Q36920433-21705E19-9FBE-46D4-B955-14306E20D6CBQ37114445-EB872BD3-E09E-46B5-83C9-40C2076CC44BQ37737793-EFE686D6-AC35-42B1-AF7A-301F3756CF0BQ38544216-3BC135A7-DE28-4E4B-B156-D800AE7AA804Q38554422-E4BEDD67-640F-4245-9C67-AEA76EC41C94Q38790630-CAF382B5-DB9B-496C-BE5E-9F6B01891818Q38806892-449BB70A-ED0C-4690-8E19-6F488AD1C384Q39608430-FBE13405-F476-4C6A-B943-B1955F85DB8BQ42011012-41154A3C-FABA-4CCC-91D4-B27FAF6FD53EQ43090573-92EF69C8-5B6C-46C0-9C04-BD2E43320131Q54979889-5AB6F4D3-8970-457E-9A33-77E74FAF364D
P2860
A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
A potential therapeutic strate ...... rosine kinase (Syk) inhibitor.
@en
A potential therapeutic strate ...... rosine kinase (Syk) inhibitor.
@nl
type
label
A potential therapeutic strate ...... rosine kinase (Syk) inhibitor.
@en
A potential therapeutic strate ...... rosine kinase (Syk) inhibitor.
@nl
prefLabel
A potential therapeutic strate ...... rosine kinase (Syk) inhibitor.
@en
A potential therapeutic strate ...... rosine kinase (Syk) inhibitor.
@nl
P2093
P2860
P921
P356
P1433
P1476
A potential therapeutic strate ...... rosine kinase (Syk) inhibitor.
@en
P2093
Astrid S Clarke
Brian J Druker
Brian J Lannutti
Julie A Dipaolo
Kevin S Currie
Marc M Loriaux
Patricia Maciejewski
Russell T Burke
Sarah Meadows
Scott A Mitchell
P2860
P304
P356
10.18632/ONCOTARGET.1484
P407
P577
2014-02-01T00:00:00Z